# Pilgrim

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pilgrim-3

- Industry: Medical Devices & Equipment
- Headquarters: Redwood City, US
- Website: www.pilgrimlabs.com
- Total disclosed funding: $29M
- Latest round: Seed (Sep 23, 2026)
- Investors on record: 10

## About

Based in the US, Pilgrim designs and produces advanced biotechnology solutions aimed at enhancing military capabilities and resilience, addressing vulnerabilities posed by emerging threats and environmental challenges.Pilgrim specializes in developing biotechnology solutions for military applications. Endorsed to Enhanced Description - In September 2026, Pilgrim raised USD 25 million in seed funding led by Buckley Ventures, with participation from Cantos, Conviction, Mantis, Magellan, Refactor Capital, Shine Capital, and Thiel Capital. The company has engaged in one deal to date with its most recent funding round occurring on August 2, 2025. Pilgrim focuses on providing tailored solutions for military organizations and has no known subsidiaries or parent companies. Specific details about the founder are not available, but the company operates under a strategic model for long-term partnerships with defense contractors.Pilgrim specializes in developing and deploying advanced biotechnology solutions specifically designed for military applications. Their core offerings focus on enhancing the capabilities and resilience of warfighters by addressing vulnerabilities associated with emerging threats and environmental challenges. The technologies aim to improve operational effectiveness through innovative applications of biological science, thereby transforming theoretical concepts into practical, battlefield-ready solutions. Pilgrim's client base primarily consists of military organizations and defense contractors, with a strategic focus on markets within North America and Europe. Their products are tailored to meet the needs of frontline personnel, ensuring that they are equipped to handle the rigors of modern warfare, thus reinforcing the human element in conflict resolution.Pilgrim's revenue model is structured around B2B transactions, primarily involving partnerships with military and defense organizations. The company engages in direct sales of its biotechnology solutions, focusing on long-term contracts and agreements that ensure continued collaboration and support for its clients. Specific pricing plans and transaction structures are designed to reflect the unique needs of military applications, often involving customized solutions that align with the operational requirements of each client. Through these strategic partnerships, Pilgrim not only provides its flagship products but also offers ongoing services to enhance and adapt its technologies as the operational landscape evolves. The company plans to utilize September 2026 funding to deploy its pathogen detection devices and support development of its airborne disease monitoring system.

## Funding rounds

- Seed, Sep 23, 2026, $25M — Refactor Capital, Thiel Capital, Mantis, Shine Capital, Buckley Ventures, Cantos, Conviction
- Seed, Aug 1, 2025, $4.3M — Thiel Capital Management, Refactor Capital, Cantos Ventures, Day One Ventures

## Investors

- Thiel Capital Management — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Cantos Ventures (https://capitalatlas.ai/funds/cantos-ventures) — Seed
- Day One Ventures (https://capitalatlas.ai/funds/day-one-ventures) — Seed
- Thiel Capital — Seed
- Mantis (https://capitalatlas.ai/funds/mantis) — Seed
- Shine Capital — Seed
- Buckley Ventures (https://capitalatlas.ai/funds/buckley-ventures) — Seed
- Cantos — Seed
- Conviction (https://capitalatlas.ai/funds/conviction) — Seed